inclusion criteria: 1. subjects male or female, aged 18 and over. 2. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). 3. sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). 4. sars-cov-2 pneumonia confirmed by chest x-ray. 5. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. 6. being within 10 days of the initial covid-19 related symptoms onset. 7. admission in the participating center within a 24hour period. 8. female patients of child-bearing age with a negative pregnancy test.

inclusion criteria: 1. subjects male or female, aged 18 and over. 2. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). 3. sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). 4. sars-cov-2 pneumonia confirmed by chest x-ray. 5. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. 6. being within 10 days of the initial covid-19 related symptoms onset. 7. admission in the participating center within a 24hour period. 8. female patients of child-bearing age with a negative pregnancy test.

inclusion criteria: subjects male or female, aged 18 and over. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). sars-cov-2 pneumonia confirmed by chest x-ray. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. being within 10 days of the initial covid-19 related symptoms onset. admission in the participating center within a 24hour period. female patients of child-bearing age with a negative pregnancy test.

inclusion criteria: subjects male or female, aged 18 and over. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). sars-cov-2 pneumonia confirmed by chest x-ray. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. being within 10 days of the initial covid-19 related symptoms onset. admission in the participating center within a 24hour period. female patients of child-bearing age with a negative pregnancy test.

inclusion criteria: 1. subjects male or female, aged 18 and over. 2. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). 3. sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). 4. sars-cov-2 pneumonia confirmed by chest x-ray. 5. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. 6. being within 10 days of the initial covid-19 related symptoms onset. 7. admission in the participating center within a 24hour period. 8. female patients of child-bearing age with a negative pregnancy test.

inclusion criteria: 1. subjects male or female, aged 18 and over. 2. acceptance to participate in the study by the signature of the informed consent by the subject or relative (if applicable). 3. sars-cov-2 infection confirmed by reverse transcriptase -polymerase chain reaction (rt-pcr). 4. sars-cov-2 pneumonia confirmed by chest x-ray. 5. patients with moderate or severe disease clinical presentation of the disease that require hospitalization. 6. being within 10 days of the initial covid-19 related symptoms onset. 7. admission in the participating center within a 24hour period. 8. female patients of child-bearing age with a negative pregnancy test.